「没有什么可失去的,却有可能获益」:一项关于癌症患者和临床医生对基于注册平台的随机对照试验可行性与可接受性的定性研究
该定性研究通过对澳大利亚15名癌症患者、15名临床医生和7名研究协调员进行半结构化访谈,探讨肿瘤学领域基于注册平台的随机对照试验(RRCT)的可行性与可接受性。研究识别出招募与入组的促进与障碍因素、患者参与体验以及未来实施建议三个主题。患者和临床医生总体支持RRCT,但有效实施仍存在若干障碍。
要点
- 患者参与RRCT的主要原因是利他主义和「对临床医生的信任」。
- 临床医生和研究协调员认为RRCT设计「简单直接」但不如RCT「令人兴奋」。
- 商业赞助RCT的竞争对研究者发起的RRCT招募构成挑战,尤其当合格患者数量少时。
核心结论
- 尽管患者、临床医生和研究协调员总体支持RRCT,但在肿瘤学领域有效实施RRCT仍存在若干障碍。
- 制定策略提高临床医生对该方法的接受度,将有助于提升RRCT在澳大利亚和国际上的采用率。
研究设计与样本
- 定性研究,对15名癌症患者、15名临床医生和7名研究协调员共37人进行半结构化访谈。
- 访谈录音并逐字转录,采用主题分析法分析数据。
主要发现
- 识别出三个总体主题:招募与入组的促进与障碍因素、患者参与RRCT的体验、对未来实施RRCT的建议。
- 对患者而言,利他主义和「对临床医生的信任」是参与RRCT的关键原因。
- 对临床医生和临床试验协调员而言,RRCT研究设计被认为「简单直接」但比RCT「不那么令人兴奋」。
- 来自商业赞助RCT的竞争对研究者发起的RRCT招募构成挑战,尤其当合格患者数量少时。
- 鉴于所探讨的RRCT涉及不同的诊疗标准,对患者治疗体验和临床医生临床工作流程的影响有限。
关键数值与推荐
- 改善患者入组RRCT的建议包括:通过教育举措提高临床医生对RRCT的认识并更广泛地宣传RRCT的「卖点」以增加临床医生的支持,以及为入组患者向医院提供经济补偿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomised controlled trials (RCTs) are considered the "gold standard" for evaluating the effectiveness of interventions in clinical research. However, conventional RCTs are typically complex, expensive, and have narrow eligibility criteria, which limits generalisability. Registry-based randomised controlled trials (RRCTs) are an alternative approach that integrates the internal validity of an RCT with the external validity of a clinical registry by recruiting real-world patients and leveraging an existing registry platform for data collection. As RRCT is a novel research design, there has been limited research on the feasibility and acceptability of RRCTs from the patients' and trial team's perspectives. This study aims to explore patients', clinicians', and study coordinators' perspectives towards participation in and conduct of oncology RRCTs in Australia. METHODS: Thirty-seven semi-structured interviews were conducted with 15 cancer patients, 15 clinicians, and 7 study coordinators. Interviews were audio-recorded and transcribed verbatim. The data were analysed using thematic analysis. RESULTS: Three overarching themes were identified: (1) enablers and barriers to recruitment and enrolment of patients in RRCTs, (2) experiences of patients participating in RRCTs, and (3) recommendations for the implementation of future RRCTs. For patients, altruism and "trust in the clinician" were key reasons to participate in a RRCT. For clinicians and clinical trial coordinators, the RRCT study design was perceived as "simple and straightforward" but "less exciting" than RCTs. Competition from commercially sponsored RCTs poses challenges for investigator-led RRCTs recruitment, particularly if eligible patient numbers are low. There were limited impacts on patients' treatment experiences and clinicians' clinical workflow given that the RRCTs explored different standards of care. Recommendations to improve the enrolment of patients in RRCTs included generating greater buy-in from clinicians by increasing awareness of RRCTs via education initiatives and broader promotion of the "selling point" of RRCTs and providing monetary compensation to hospitals for enrolling patients. CONCLUSIONS: Whilst patients, clinicians, and study coordinators were generally supportive of RRCTs, several barriers to effective RRCT implementation in oncology were identified. Developing strategies to increase acceptance of the methodology by clinicians will help enhance the uptake of RRCTs in Australia and internationally.
引用
- Prang KH, Karanatsios B, Zhang A, et al. "Nothing to lose and the possibility of gaining": a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians. Trials. 2023. PMID: 36747274. doi:10.1186/s13063-023-07109-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。